July 8, 2010

 

EU authorises pig oral suspension Metacam^®

Boehringer Ingelheim's Animal Health medication Metacam^® obtained EU wide marketing authorisation as an oral suspension in a concentration of 15 mg/ml for use in pigs.

 

Metacam^® reduces symptoms of lameness and inflammation in animals suffering from non-infectious locomotor disorders and acts as adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (Mastitis-Metritits-Agalactia syndrome, MMA).

 

The European Medicines Agency's (EMA) scientific committee and the EU commission announced their decision to authorise this new formulation of Metacam^® for pigs.

 

Metacam^® 15 mg/ml controls inflammation and restores productivity in pigs. Freshly farrowed sows which are particularly sensitive to stress can use the oral application rather than an injection.

 

"Metacam^® 15 mg/ml oral suspension is all about choices which we try to offer to the swine producer enabling him to better adjust the administration of a needed treatment to specific conditions", said Dr. Joachim Hasenmaier, Head of Corporate Animal Health at Boehringer Ingelheim.

 

Metacam^® is a non-steroidal anti-inflammatory drug of the oxicam class.  Metacam^® was first launched for pigs in 2003, and is now licensed in over 40 countries.